This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Levosimendan Versus Dobutamine in Shock Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2004 by Wentworth Area Health Services.
Recruitment status was:  Recruiting
Information provided by:
Wentworth Area Health Services Identifier:
First received: October 5, 2004
Last updated: June 23, 2005
Last verified: October 2004
The purpose of the study is to compare the efficacy of levosimendan with that of dobutamine in patients with unstable hemodynamics (shock).

Condition Intervention Phase
Cardiogenic Shock Septic Shock Drug: Levosimendan Drug: Dobutamine Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Efficacy of Levosimendan in the Critically Ill Patients With Unstable Hemodynamics (the LICI Study) - A Double Blind Randomized Pilot Study

Resource links provided by NLM:

Further study details as provided by Wentworth Area Health Services:

Primary Outcome Measures:
  • Resolution of shock state

Secondary Outcome Measures:
  • Change in cardiac functions

Estimated Enrollment: 40
Study Start Date: October 2004
Estimated Study Completion Date: April 2006

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Reduced left ventricular systolic function
  • Hypotension
  • Anuria or oligouria

Exclusion Criteria:

  • Less than 18 years old
  • Pregnant
  • Uncorrected valvular stenosis
  • Hypertrophic obstructive cardiomyopathy (HOCM)
  • Third degree AV block
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00093301

Australia, New South Wales
Intensive Care Unit, Nepean Hospital Recruiting
Penrith, New South Wales, Australia, 2750
Contact: Anthony S McLean, MD    +61-2-47342490   
Contact: Stephen J Huang, PhD    +61-247342320   
Principal Investigator: Anthony S McLean, MD         
Sub-Investigator: Stephen J Huang, PhD         
Sub-Investigator: Ian Seppelt, MD         
Sub-Investigator: Marek Nalos, MD         
Sponsors and Collaborators
Wentworth Area Health Services
  More Information Identifier: NCT00093301     History of Changes
Other Study ID Numbers: 03/007
Study First Received: October 5, 2004
Last Updated: June 23, 2005

Keywords provided by Wentworth Area Health Services:
Heart failure

Additional relevant MeSH terms:
Shock, Septic
Shock, Cardiogenic
Pathologic Processes
Systemic Inflammatory Response Syndrome
Myocardial Infarction
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Cardiotonic Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Anti-Arrhythmia Agents
Phosphodiesterase Inhibitors
Enzyme Inhibitors processed this record on September 21, 2017